
Genovis - Bull Story, Fair Price

Redeye returns with an updated take on the pick-and-shovel play Genovis following a site visit and change of lead analyst. We consider the cutting-edge enzyme producer well positioned for growth and see the current share price at an attractive level for a rapidly expanding compounder with compelling optionality.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Genovis - Bull Story, Fair Price